Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

globenewswire

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions – NEWSnet – News… as it used to be

More Press Releases

May 6, 2026

Aura Announces Q1 2026 Financial and Operational Results, Another High Record Adjusted EBITDA

May 6, 2026

Ballad Health Academy welcomes second class of students amid new program offerings and expansions

May 6, 2026

Crypto News: Pepeto Presale Stages Update While Markets Ask if the XRP Price Prediction Can Reach $100

May 6, 2026

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Aura Announces Q1 2026 Financial and Operational Results, Another High Record Adjusted EBITDA

Ballad Health Academy welcomes second class of students amid new program offerings and expansions

Crypto News: Pepeto Presale Stages Update While Markets Ask if the XRP Price Prediction Can Reach $100

RGC Investors Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit